Pre-surgery use of Bristol's Opdivo 'safe and feasible' in lung cancer, study shows


COPENHAGEN, Denmark--Bristol-Myers Squibb’s first-line hopes for immuno-oncology star Opdivo recently took a gut check when the med flopped in a Phase III study. But now, researchers say there’s reason to be optimistic about a potential neoadjuvant nod for the medicine down the line.

Pre-surgery lung cancer treatment with the immunotherapy drug is “safe and feasible,” investigators reported Friday at the ESMO 2016 Congress. They reported results from 16 patients, among whom they found no significant safety concerns or delays to surgery after Opdivo treatment.

The study was the first to test a PD-1 treatment in early stage lung cancer; previously, trial data from Opdivo and its in-class competitors had only been reported in metastatic or advanced forms of the disease, lead study author Patrick Forde pointed out in a statement.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

And these days--as the immuno-oncology space heats up--PD-1 and PD-L1 drugmakers are racing to stake their claims in markets yet untouched by the revolutionary cancer-fighters.

Bristol was doing just that with its quest to land a first-line lung cancer nod. Currently, it shares the second-line space with archrival Keytruda from Merck & Co., and both have Roche’s third-to-market Tecentriq, an FDA-designated breakthrough drug that’s nearing its first lung cancer nod, nipping at their heels.

Things didn’t exactly go as planned for the New Jersey pharma giant, though, which reported in August that the med had missed its mark in a key trial. Shares plunged accordingly, with Bernstein’s Tim Anderson writing to clients that the failure put Bristol “on its back foot from a commercial perspective.”

Related Articles: 
Roche's Tecentriq steps up to challenge Keytruda, Opdivo with new lung cancer data
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights 
BMS loses its lung cancer lead to Merck as Opdivo data comes up short 
Bristol's Opdivo-Yervoy combo ups response rates in first-line lung cancer patients 
Merck's Keytruda tops chemo in first-line lung cancer trial 
Merck's Keytruda held back by docs who don't want to wait for diagnostics

Suggested Articles

Several Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company's overall performance.

J&J has received its fair share of barbs Oklahoma's bench trial. Whether it'll be held responsible for the state's opioid crisis is now up…

J&J's pharma unit is still on the upswing, thanks to newer meds like Stelara, but execs had to explain disappointing numbers from two blockbusters.